256 related articles for article (PubMed ID: 19460715)
1. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
Liao N; Zhang GC; Li XR; Yao M; Wang K
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
[TBL] [Abstract][Full Text] [Related]
2. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
3. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
4. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Valachis A; Nearchou A; Lind P; Mauri D
Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
10. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
[TBL] [Abstract][Full Text] [Related]
12. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M; Macrae ER; Abdel-Rasoul M; Layman R; Friedman S; Querry J; Lustberg M; Ramaswamy B; Mrozek E; Shapiro C; Wesolowski R
Oncologist; 2015 Apr; 20(4):337-43. PubMed ID: 25732265
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
20. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
